Zynteglo halt re-ignites viral vector safety concerns; analysts
pharmaphorum
FEBRUARY 22, 2021
That is concentrating on determining where the vector integrated into the chromosomes of the two patients with cancer, and if that has resulted in changes to gene expression in neighbouring areas. The case comes just weeks after UniQure halted a trial of its haemophilia B gene therapy AMT-061 after an unexpected case of liver cancer.
52 
Let's personalize your content